HUMAX-CD4 STUDY

Article

Genmab A/S presented data from Phase II HuMax-CD4 studies to treat cutaneous T-cell lymphoma (CTCL) at the 65th annual meeting of the Society for Investigative Dermatology in April. At the time the abstract was completed, 36 patients enrolled in the two ongoing HuMax-CD4 clinical trials were evaluated using the Composite Assessment of Index Lesion Disease Activity (CA) score.

Related Videos
Related Content

Pointers With Portela: Treating Fungal Acne

September 25th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

POLL: What Strategies Have You Found Most Effective in Managing Alopecia?

September 25th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Derm In The News: September 17-23

September 23rd 2023

The Weekly Roundup: September 18-22

September 22nd 2023

Pointers With Portela: Treating Fungal Acne

September 25th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

POLL: What Strategies Have You Found Most Effective in Managing Alopecia?

September 25th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Derm In The News: September 17-23

September 23rd 2023

The Weekly Roundup: September 18-22

September 22nd 2023

Pointers With Portela: Treating Fungal Acne

September 25th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

POLL: What Strategies Have You Found Most Effective in Managing Alopecia?

September 25th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Derm In The News: September 17-23

September 23rd 2023

The Weekly Roundup: September 18-22

September 22nd 2023
© 2023 MJH Life Sciences

All rights reserved.